NewLimit, the San Francisco-based longevity biotechnology company co-founded by Coinbase CEO Brian Armstrong, announced a $435 million Series C financing round on June 2, bringing its total valuation to approximately $3.1 billion. The round was led by Founders Fund, with participation from Thrive Capital, Greenoaks, Kleiner Perkins, Eli Lilly Ventures, and several other institutional and individual investors.
The financing follows what NewLimit describes as a prototype discovery: a candidate medicine that reverses the epigenetic age of old human liver cells in preclinical models. The company reports that in aged liver tissue, treatment with its lead mRNA construct increased regenerative capacity and improved resilience to alcohol-related cellular stress — phenotypes associated with youthful hepatic function that degrade with age.
The technology platform is built on epigenetic reprogramming, the idea that the epigenome — the layer of chemical marks that regulate gene expression without altering the underlying DNA sequence — accumulates age-associated changes that drive functional decline. NewLimit’s approach uses lipid nanoparticle-delivered mRNA to instruct cells to reset these epigenetic marks, drawing on Yamanaka factor biology while seeking to avoid the oncogenic risk associated with full reprogramming to a pluripotent state.
Liver disease was selected as the initial clinical indication for several reasons. Hepatic aging creates measurable, disease-relevant functional decline. Fatty liver disease — encompassing metabolic dysfunction-associated steatotic liver disease (MASLD) and the more severe metabolic dysfunction-associated steatohepatitis (MASH) — represents an enormous unmet need, with an estimated 25 percent of the global adult population affected and limited approved treatments. The liver’s ability to take up LNP-RNA medicines efficiently, given its natural role in lipoprotein metabolism, provides a practical delivery advantage.
The $435 million will support IND-enabling studies and Phase I trial initiation, which NewLimit plans for 2027. The trial will enrol patients with advanced fatty liver disease, establishing safety, tolerability, and early efficacy signals in a patient population where cellular age reversal could translate to clinically meaningful improvements in hepatic function.
NewLimit is not alone in pursuing epigenetic reprogramming as a therapeutic modality. Alto Bioscience and Altos Labs — the latter backed by over $3 billion since its 2022 launch — are developing related approaches, and a broader wave of longevity capital has entered the sector over the past two years. However, NewLimit’s Series C valuation and the specificity of its liver cell preclinical data represent a meaningful step toward translational credibility in a field that has long been rich with promise but thin on clinical evidence.
The broader 2026 biotech funding environment has been supportive, with investors returning to growth-stage companies after the sector-wide contraction of 2022 to 2023. Longevity biology sits at the intersection of multiple validated drug development paradigms and has attracted both traditional life sciences investors and technology-sector capital.
